Diet Induced Obesity Model for Cancer Research
A More Clinically Relevant Model to Uncover Your Treatment’s Potential
Obesity is a risk factor for at least 13 different forms of cancer. Mechanisms in which obesity and changes in systemic metabolism affect the tumor microenvironment (TME) and impact antitumor immunity are unclear. Current preclinical models use mouse strains which are fed a controlled diet and therefore host mice are not representative of Western human cancer populations. TD2 has established a diet induced obesity tumor model (Figure 1) to screen cancer therapies in a more clinically relevant system.
Figure 1: Establishment of diet induced obesity mouse tumor model
Benefits of Diet Induced Obesity Mouse Models:
- Execute studies in more clinically relevant models reflective of the significant rates of obesity projected by 2035.
- Understand how obesity induced systemic changes in metabolism effect the tumor microenvironment
- Identify new treatments/mechanism of action that may show increased therapeutic benefit in DIO models
- Quantify metabolite and proteomic changes in response to treatment that could be used as biomarkers of treatment benefit or as opportunity for new targets for drug development